Company Performance - Abbott's stock closed at $128.47, reflecting a +2.4% change from the previous day's closing price, outperforming the S&P 500's loss of 0.16% [1] - Over the past month, Abbott's shares have decreased by 3.93%, underperforming the Medical sector's gain of 1.12% and the S&P 500's loss of 0.21% [1] Upcoming Financial Results - Abbott's upcoming EPS is projected at $1.5, indicating an 11.94% increase compared to the same quarter of the previous year [2] - Revenue is expected to reach $11.79 billion, representing a 7.48% growth compared to the corresponding quarter of the prior year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $5.15 per share and revenue at $44.6 billion, reflecting changes of +10.28% and +6.33% respectively from the prior year [3] Analyst Estimates - Recent adjustments to analyst estimates for Abbott are important as they indicate changing near-term business trends, with upward revisions suggesting analysts' positivity towards the company's operations [4] - The consensus EPS projection has remained stable over the past 30 days, and Abbott currently holds a Zacks Rank of 3 (Hold) [6] Valuation Metrics - Abbott's Forward P/E ratio is 24.37, which is a premium compared to the industry average Forward P/E of 19.3 [6] - The company has a PEG ratio of 2.29, while the average PEG ratio for Medical - Products stocks is 1.92 [7] Industry Context - The Medical - Products industry, part of the Medical sector, has a Zacks Industry Rank of 165, placing it in the bottom 34% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Key Takeaways ABT rolled out Android support for Lingo, its first biowearable CGM, extending use beyond Apple devices.Lingo targets adults not on insulin, showing how diet, exercise and stress affect glucose levels in real time.Android access supports ABT's push to make CGMs a mainstream wellness tool for diabetes and prediabetes care.Abbott Laboratories (ABT) recently announced that Lingo, its first over-the-counter biowearable continuous glucose monitor system (CGM), can now be used with Android devices. ...

Core Viewpoint - The article emphasizes the importance of incorporating dividend-paying stocks into an investment portfolio, highlighting their ability to provide passive income and mitigate losses during market downturns [2][3]. Group 1: Dividend Stocks Overview - Dividend-paying stocks can provide extra cash flow regardless of market conditions, making them a valuable addition to any portfolio [2]. - Dividend Kings, companies that have increased their dividend payments for at least 50 consecutive years, are highlighted as wise investment choices due to their commitment and ability to sustain dividends over time [3]. Group 2: Company Profiles - **Coca-Cola (KO)**: - The company is the largest non-alcoholic beverage producer globally, with a market cap of $303 billion and a dividend yield of 2.89%, having increased its dividend for over 60 years [7][5]. - Current share price is $70.52, with a dividend payment of $2.04 per share [6][7]. - **Abbott Laboratories (ABT)**: - A healthcare giant with a diversified business model across medical devices, nutrition, diagnostics, and pharmaceuticals, offering a market cap of $218 billion and a dividend yield of 1.88% [10][12]. - The current share price is $125.46, with a dividend payment of $2.36 per share, and has increased its dividend for 53 years [12][13]. - **Target (TGT)**: - The retailer is undergoing a recovery phase with a new CEO and has a market cap of $44 billion, boasting a dividend yield of 4.66% [14][16]. - Current share price is $97.09, with a dividend payment of $4.56 per share, and has increased its dividend for 54 years [18].

Core Insights - The "High Income DIY Portfolios" service aims to provide high income with low risk and capital preservation for DIY investors, particularly targeting income investors such as retirees [1][2] - The service offers a total of 10 model portfolios, including various strategies like buy-and-hold and rotational portfolios, designed to create stable, long-term passive income with sustainable yields [1][2] Group 1: Portfolio Strategies - The service includes seven portfolios: three buy-and-hold, three rotational, and a conservative NPP strategy portfolio, focusing on low drawdowns and high growth [1] - The portfolios are categorized into two High-Income portfolios, two Dividend Growth Investing (DGI) portfolios, and a conservative NPP strategy [1] Group 2: Investment Approach - The investment approach emphasizes a unique 3-basket strategy that targets 30% lower drawdowns and aims for a 6% current income with market-beating growth over the long term [2] - The service provides buy and sell alerts, as well as live chat for real-time support and guidance [2]

Core Insights - The S&P 500 has experienced a strong bull market over the past three years, with gains exceeding 20% in each of the last two years, driven primarily by technology stocks and optimism regarding lower interest rates [2][3] Company Summaries - **Nvidia**: Positioned to benefit from AI infrastructure spending, which could reach trillions over the next five years, and has seen significant earnings growth due to its leadership in AI chip design [5][6] - **Eli Lilly**: Earnings have surged due to its weight loss drug portfolio, particularly Tirzepatide, and the company is advancing its oral weight loss candidate, orforglipron, towards commercialization [6][7][8] - **American Express**: A strong player in the payment card market, benefiting from a high-income customer base, with 64% of new accounts coming from younger customers, indicating future growth potential [9][10] - **CoreWeave**: Experienced a significant stock increase of over 300% since its market launch, focusing on providing AI customers with high-capacity workloads, suggesting strong revenue growth ahead [12][14] - **Viking Therapeutics**: Aiming to enter the billion-dollar weight loss drug market with promising phase 2 and phase 3 trial results for its injectable and oral candidates, respectively [15][16] - **Meta Platforms**: Trading at 26x forward earnings, it is the most affordable among leading tech stocks, with a strong commitment to AI investment and revenue growth [17][19] - **Abbott Laboratories**: A Dividend King with over 50 years of dividend growth, diversified across multiple healthcare sectors, and strong free cash flow [20][22] - **UnitedHealth Group**: The largest U.S. health insurer, addressing rising healthcare costs and increasing its earnings guidance, making it a potential recovery story [23][24] - **Chewy**: An e-commerce leader in pet products with over 80% of net sales from its AutoShip program, indicating strong customer loyalty and profitability [26][27] - **Amazon**: A market giant with a strong growth trajectory in e-commerce and cloud computing, leveraging AI to enhance efficiency and revenue, currently trading at 32x forward earnings [28][30][31]

Quarterly dividend increased by 6.8% Quarterly dividend payout has increased more than 70% since 2020 th408 consecutive quarterly dividend to be paid by Abbott since 1924 ABBOTT PARK, Ill., Dec. 12, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase of 6.8%. The company's quarterly dividend payout has increased more than 70% since 2020. ththThis marks Abbott's 54 consecutive year of d ...

The company that makes one of the two most widely used brands of formula for premature babies is threatening to stop. That is, unless US health officials and Congress help protect it from lawsuits related to infant deaths allegedly tied to its product.It’s a warning that holds particular power over policy makers and legislators who’ve become acutely aware of the fragility of a baby formula market that’s been mired in recent scandals. The biggest players in the market have struggled with shortages in recent ...

A flood of baby formula lawsuits that could cost Abbott billions have it on the offensive — and asking for the government to intervene. https://t.co/FhkFNeRo29 ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

24/7 Wall St. Quick Read Abbott Laboratories (ABT) grew revenue 6.9% with medical devices up 14.8% to $5.45B. Abbott reaffirmed guidance for 7.5-8.0% organic growth. Eli Lilly (LLY) posted 54% revenue growth driven by Mounjaro ($6.52B) and Zepbound ($3.57B). Lilly raised guidance to $63.0-63.5B revenue. Lilly’s operating margin reached 48.3% versus Abbott’s 19.4%. Lilly trades at 49.5x P/E while Abbott trades at 15.71x. If you’re thinking about retiring or know someone who is, there are three quic ...